Author

J. M. Powers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. S. Baric· 4 shared D. Veesler· 2 shared J. E. Munt· 2 shared L. E. Adams· 2 shared N. P. King· 2 shared R. J. Edwards· 2 shared S. R. Leist· 2 shared A. Brown· 1 shared

Activity by Year

2023-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

R. S. Baric

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination

W. N. Voss, M. A. Mallory, P. O. Byrne, J. M. Marchioni, S. A. Knudson, J. M. Powers, S. R. Leist, B. Dadonaite, D. R. Townsend, J. Kain, Y. Huang, E. Satterwhite, I. N. Castillo, M. Mattocks, C. Paresi, , G. C. Ippolito

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

Cell Reports Medicine · Aug 1, 2024Peer-reviewedImmunology

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines

J. Lee, C. Stewart, A. Schaefer, E. M. Leaf, Y.-J. Park, D. Asarnow, J. M. Powers, C. Treichel, D. Corti, R. Baric, N. P. King, D. Veesler

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

bioRxiv · Dec 12, 2023Biochemistry

Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice

D. Martinez, A. R. Schaefer, T. Gavitt, M. Mallory, E. Lee, N. Catanzaro, H. Chen, K. Gully, T. D. Scobey, P. Korategere, A. Brown, L. Smith, R. Parks, M. Barr, A. Newman, , K. O. Saunders

This study develops a trivalent RBD nanoparticle vaccine that protects mice against both merbecovirus and sarbecovirus challenges, including SARS-CoV, MERS-CoV, and SARS-CoV-2.

Cell Reports · Oct 1, 2023Peer-reviewedImmunology

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

C. N. Pierre, L. E. Adams, K. Anasti, D. Goodman, S. Stanfield-Oakley, J. M. Powers, D. Li, W. Rountree, Y. Wang, R. J. Edwards, S. M. Alam, G. Ferrari, G. D. Tomaras, B. F. Haynes, R. S. Baric, K. Saunders

This study shows non-neutralizing SARS-CoV-2 antibodies protect mice from severe disease via Fc-mediated effector functions, reducing viral load and lung damage.

bioRxiv · Jul 25, 2023Immunology

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

Y. Feng, M. Yuan, J. M. Powers, M. Hu, J. E. Munt, P. S. Arunachalam, S. R. Leist, L. Bellusci, L. E. Adams, S. Sundaramurthy, L. M. Shirreff, M. L. Mallory, T. D. Scooby, A. Moreno, D. T. OHagan, , B. Pulendran

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

bioRxiv · Jan 19, 2023 · PreprintImmunology